RGC: נכסי החברה Regencell Corp

Regencell Bioscience develops treatments for autism and ADHD based on Chinese medicine, minimizing R&D risks. However, its venture status and a narrow niche involving expensive testing constrain growth. The structure of total balance sheet assets clearly demonstrates the firm's resources, where the value of 10.24 serves as a baseline indicator. A lack of pricing power will necessitate aggressive marketing to realize the premium value of future drugs.

Total assets reflect the aggregate value of the company's resources, formed through equity and debt to support operational activities. By analyzing the history of controlled resources, calculated reverse-engineered via ROA, an investor assesses the financial base of Regencell Bioscience (RGC) required for the commercialization of traditional Chinese medicine formulas for the therapy of ADHD and autism spectrum disorders.